The announcement by Mark Engel, the Company's Chairman and CEO, signifies a greater commitment to the US market

该公司董事长兼首席执行官马克·恩格尔（Mark Engel）的这一宣布意味着对美国市场的更大承诺

DOVER, Del., Jan. 23, 2024 /PRNewswire/ -- Precisio Biotix Therapeutics ('Precisio') today announced the hiring of Dr. Raymond (Ray) Schuch as Vice President, Director of US Operations.

多佛，Del。，2024年1月23日/PRNewswire/--Precisio Biotix Therapeutics（“Precisio”）今天宣布聘请Raymond（Ray）Schuch博士为副总裁兼美国运营总监。

Precisio creates novel lower cost precision biological antibacterials with a focus on lung and skin infections. The Company's key assets include: (1) LysiThru™, the company's industry leading high through put screening, engineering and AI system for creating best or first in class novel lysins (engineered precision enzymes that rapidly break targeted bacterial cell walls without causing resistance); (2) a strong pipeline of lysin and phage products that will be able to address multiple problematic bacterial diseases, including antibiotic resistant (AMR) infections; and (3) one of the strongest scientific teams to address the global need for novel medicines to fight AMR infections.

Precisio创建了新型低成本精密生物抗菌剂，重点关注肺部和皮肤感染。公司的主要资产包括：（1）LysiThru™, 该公司业界领先的高通量筛选，工程和人工智能系统，用于创建最佳或一流的新型赖氨酸（工程精密酶，可快速破坏目标细菌细胞壁而不产生耐药性）；（2） 强大的赖氨酸和噬菌体产品管道，将能够解决多种有问题的细菌疾病，包括抗生素耐药性（AMR）感染；（3）是解决全球对抗AMR感染新药需求的最强科学团队之一。

.

.

Mark stated 'We are delighted to welcome Ray to our team since he is one of the strongest scientists globally in the lysin field.  Lysins are one of the potential new modalities for treating AMR infections. Lysins are enzymes that rapidly break down the cell walls of bacteria without creating new resistance and therefore can be used as alternatives to traditional antibiotics, particularly where the traditional antibiotics no longer work well against specific antibiotic resistant infections.

马克表示：“我们很高兴欢迎雷加入我们的团队，因为他是赖氨酸领域全球最强大的科学家之一。赖氨酸是治疗AMR感染的潜在新方式之一。赖氨酸是一种酶，可以快速分解细菌的细胞壁而不会产生新的耐药性，因此可以用作传统抗生素的替代品，特别是在传统抗生素对特定抗生素耐药性感染不再有效的情况下。

We believe that our engineering process is more effective than anyone else's in the world.'.

我们相信我们的工程流程比世界上任何其他公司都更有效。”。

Mark further stated that 'Ray has joined in order to: (1) more quickly develop and register our novel medicines and (2) work more effectively with our financial, medical, hospital, government and business partners in the US.'

Mark进一步表示，“Ray的加入是为了：（1）更快地开发和注册我们的新药；（2）更有效地与我们在美国的金融、医疗、医院、政府和商业合作伙伴合作。”

Ray further added 'I am thrilled to join such an experienced and effective team with the goal of bringing a new and cutting-edge antimicrobial modality into human therapeutic use for the treatment of severe and life-threatening infections with antibiotic resistant microorganisms.  The threat from AMR and its impact on human health becomes more significant each year and must be met with a pipeline of new effective agents, such as lysins and phages, with novel mechanisms of action distinct from antibiotics.  Their notable commitment to bringing such precision antimicrobials into clinical use was a driving factor in my decision to join Precisio, as was the opportunity to work with such a dynamic and successful team.'.

Ray进一步补充道：“我很高兴加入这样一个经验丰富且有效的团队，目标是将一种新的尖端抗菌方式引入人类治疗用途，用于治疗严重且危及生命的抗生素耐药微生物感染。AMR的威胁及其对人类健康的影响每年都变得更加严重，必须通过一系列新的有效药物（如赖氨酸和噬菌体）来应对，这些药物具有不同于抗生素的新作用机制。他们对将这种精密抗菌剂用于临床的显着承诺是我决定加入Precisio的一个驱动因素，也是与这样一个充满活力和成功的团队合作的机会。”。

ABOUT PRECISIO BIOTIX THERAPEUTICS

关于PRECISIO BIOTIX THERAPEUTICS

Precisio is a family funded clinical stage biotech creating engineered novel lower cost precision biological antibacterials, with an initial focus on skin and lung infections. Precisio is a platform plus product company (Rx, consumer). Management has had multiple previous successful exits. Precisio is currently looking to add strategic and impact investors. .

Precisio是一家由家庭资助的临床阶段生物技术公司，创建了工程化的新型低成本精密生物抗菌剂，最初专注于皮肤和肺部感染。Precisio是一家平台加产品公司（Rx，消费者）。管理层曾多次成功退出。Precisio目前正在寻求增加战略和影响力投资者。。

Contact: Aileen Shen, Director of Investor Relations, at [email protected]

联系人：投资者关系总监Aileen Shen，网址[受电子邮件保护]

SOURCE Precisio Biotix Therapeutics, Inc.

来源Precisio Biotix Therapeutics，Inc。